أعرض في EDS

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines.

التفاصيل البيبلوغرافية
العنوان: A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines.
المؤلفون: Lee J; Department of Biochemistry, University of Washington, Seattle, Washington, USA., Stewart C; Department of Biochemistry, University of Washington, Seattle, Washington, USA., Schaefer A; Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA., Leaf EM; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Park YJ; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Howard Hughes Medical Institute, Seattle, WA 98195, USA., Asarnow D; Department of Biochemistry, University of Washington, Seattle, Washington, USA., Powers JM; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, Seattle, WA 98195, USA.; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Treichel C; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Baric R; Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA., King NP; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Veesler D; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Howard Hughes Medical Institute, Seattle, WA 98195, USA.
المصدر: BioRxiv : the preprint server for biology [bioRxiv] 2023 Dec 20. Date of Electronic Publication: 2023 Dec 20.
نوع المنشور: Preprint
اللغة: English
بيانات الدورية: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
مستخلص: Continuous evolution of SARS-CoV-2 alters the antigenicity of the immunodominant spike (S) receptor-binding domain and N-terminal domain, undermining the efficacy of vaccines and monoclonal antibody therapies. To overcome this challenge, we set out to develop a vaccine focusing antibody responses on the highly conserved but metastable S 2 subunit, which folds as a spring-loaded fusion machinery. Here, we describe a protein design strategy enabling prefusion-stabilization of the SARS-CoV-2 S 2 subunit and high yield recombinant expression of trimers with native structure and antigenicity. We demonstrate that our design strategy is broadly generalizable to all sarbecoviruses, as exemplified with the SARS-CoV-1 (clade 1a) and PRD-0038 (clade 3) S 2 fusion machineries. Immunization of mice with a prefusion-stabilized SARS-CoV-2 S 2 trimer vaccine elicits broadly reactive sarbecovirus antibody responses and neutralizing antibody titers of comparable magnitude against Wuhan-Hu-1 and the immune evasive XBB.1.5 variant. Vaccinated mice were protected from weight loss and disease upon challenge with SARS-CoV-2 XBB.1.5, providing proof-of-principle for fusion machinery sarbecovirus vaccines motivating future development.
Competing Interests: Competing Interests N.P.K. and D.V. are named as inventors on patents for coronavirus nanoparticle vaccines filed by the University of Washington. N.P.K. is a co-founder, shareholder, paid consultant,and chair of the scientific advisory board of Icosavax, Inc. and has received an unrelated sponsored research agreement from Pfizer. D.C. is an employee of Vir Biotechnology and may hold shares in Vir Biotechnology.
التعليقات: Update in: Nat Commun. 2024 Jun 28;15(1):5496. doi: 10.1038/s41467-024-49656-5. (PMID: 38944664)
References: Science. 2022 Aug 12;377(6607):735-742. (PMID: 35857703)
Science. 2021 Aug 6;373(6555):648-654. (PMID: 34210893)
Nat Struct Mol Biol. 2015 Nov;22(11):833-4. (PMID: 26581513)
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. (PMID: 20057044)
Sci Transl Med. 2021 Jun 30;13(600):. (PMID: 34103407)
N Engl J Med. 2022 Oct 6;387(14):1279-1291. (PMID: 36112399)
Nature. 2022 Feb;602(7896):300-306. (PMID: 34823256)
Science. 2021 Jun 18;372(6548):1336-1341. (PMID: 34006597)
Nat Methods. 2019 Nov;16(11):1153-1160. (PMID: 31591578)
Science. 2022 Jan 28;375(6579):449-454. (PMID: 34990214)
Nature. 2023 Feb;614(7948):521-529. (PMID: 36535326)
Structure. 2019 Jan 2;27(1):134-139.e3. (PMID: 30344107)
Cell. 2020 Nov 25;183(5):1367-1382.e17. (PMID: 33160446)
Nature. 2022 Feb;602(7898):664-670. (PMID: 35016195)
J Comput Chem. 2004 Oct;25(13):1605-12. (PMID: 15264254)
Nature. 2020 Oct;586(7830):567-571. (PMID: 32756549)
Sci Immunol. 2022 Nov 18;7(77):eabq7647. (PMID: 35943359)
Science. 2022 Nov 25;378(6622):eabo2523. (PMID: 36302057)
Sci Immunol. 2022 Oct 28;7(76):eadd4853. (PMID: 35857583)
Nat Methods. 2017 Mar;14(3):290-296. (PMID: 28165473)
Elife. 2016 Sep 26;5:. (PMID: 27669148)
Nature. 2023 Sep;621(7979):592-601. (PMID: 37648855)
J Mol Biol. 2012 Jan 13;415(2):406-18. (PMID: 22100448)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Science. 2022 Nov 11;378(6620):619-627. (PMID: 36264829)
Cell Rep. 2022 Dec 20;41(12):111845. (PMID: 36493787)
Nature. 2021 Jun;594(7862):253-258. (PMID: 33873199)
Science. 2020 Sep 18;369(6510):1501-1505. (PMID: 32703906)
IUCrJ. 2019 Jan 01;6(Pt 1):5-17. (PMID: 30713699)
Nature. 2021 Sep;597(7874):97-102. (PMID: 34261126)
Nat Med. 2023 Jan;29(1):247-257. (PMID: 36265510)
J Mol Biol. 2003 Oct 31;333(4):721-45. (PMID: 14568533)
Cell Rep. 2023 Apr 25;42(4):112326. (PMID: 37000623)
Nat Med. 2021 Dec;27(12):2108-2110. (PMID: 34728830)
Science. 2021 Dec 24;374(6575):1621-1626. (PMID: 34751595)
Nat Commun. 2023 Apr 10;14(1):2003. (PMID: 37037866)
Nat Commun. 2021 Mar 17;12(1):1715. (PMID: 33731724)
Cell. 2022 Mar 3;185(5):872-880.e3. (PMID: 35123650)
Cell. 2022 Mar 3;185(5):847-859.e11. (PMID: 35139340)
Science. 2021 Sep 03;373(6559):1109-1116. (PMID: 34344823)
Science. 2022 Aug 12;377(6607):728-735. (PMID: 35857439)
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11157-11162. (PMID: 29073020)
Nature. 2016 Mar 3;531(7592):114-117. (PMID: 26855426)
Elife. 2023 Mar 21;12:. (PMID: 36942851)
Ultramicroscopy. 2013 Dec;135:24-35. (PMID: 23872039)
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002)
Science. 2020 Nov 20;370(6519):950-957. (PMID: 32972994)
Cell Rep. 2022 May 17;39(7):110829. (PMID: 35550680)
Nat Struct Mol Biol. 2021 Jun;28(6):478-486. (PMID: 33981021)
Nature. 2022 Feb;602(7898):657-663. (PMID: 35016194)
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877. (PMID: 31588918)
Nature. 2024 Jan;625(7993):148-156. (PMID: 37993710)
Sci Immunol. 2022 Dec 23;7(78):eadf1421. (PMID: 36356052)
Cell Host Microbe. 2023 Dec 13;31(12):1961-1973.e11. (PMID: 37989312)
Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2314392120. (PMID: 38011546)
Cell Rep. 2021 Nov 2;37(5):109929. (PMID: 34710354)
EClinicalMedicine. 2022 Jul 22;51:101569. (PMID: 35879941)
Elife. 2018 Nov 09;7:. (PMID: 30412051)
Nat Commun. 2017 Apr 10;8:15092. (PMID: 28393837)
Nat Methods. 2020 Dec;17(12):1214-1221. (PMID: 33257830)
Nat Microbiol. 2022 Jul;7(7):1063-1074. (PMID: 35773398)
J Struct Biol. 2005 Jul;151(1):41-60. (PMID: 15890530)
Sci Immunol. 2021 Dec 10;6(66):eabj5129. (PMID: 34890255)
Cell. 2020 Nov 12;183(4):1024-1042.e21. (PMID: 32991844)
Nat Methods. 2019 Nov;16(11):1146-1152. (PMID: 31591575)
Science. 2022 Feb 25;375(6583):864-868. (PMID: 35076256)
Nature. 2021 Nov;599(7883):114-119. (PMID: 34488225)
Protein Sci. 2018 Jan;27(1):14-25. (PMID: 28710774)
Cell. 2019 Feb 21;176(5):1026-1039.e15. (PMID: 30712865)
Cell. 2021 Apr 29;184(9):2332-2347.e16. (PMID: 33761326)
J Struct Biol. 2012 Dec;180(3):519-30. (PMID: 23000701)
معلومات مُعتمدة: 75N93022C00036 United States AI NIAID NIH HHS; DP1 AI158186 United States AI NIAID NIH HHS; P01 AI167966 United States AI NIAID NIH HHS
تواريخ الأحداث: Date Created: 20240103 Latest Revision: 20240708
رمز التحديث: 20240708
مُعرف محوري في PubMed: PMC10760017
DOI: 10.1101/2023.12.12.571160
PMID: 38168207
قاعدة البيانات: MEDLINE
الوصف
تدمد:2692-8205
DOI:10.1101/2023.12.12.571160